IQVIA艾昆纬：2026年340B返佣是否给340B提供商带来了巨大的财务负担？（英文版）

In 2025, the Health Resources and Services Administration (HRSA) proposed transitioning the 340B Drug Pricing Program (“340B program”) to a rebate model. While 340B hospitals and others expressed concerns, some patient advocates and covered entity types already using a rebate model expressed support. A court enjoined (prohibited via an injunction) the pilot after crediting 340B provider trade association representations that purchasing drugs at list price and receiving a 340B rebate at a late